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ABSTRACT
INTRODUCTION: The development and implementation of test systems in pharmacy practice could be 
one of the ways of optimization of the quality control of compounded preparations. Test kits, which have 
been manufactured in a pharmacy, are simple, cheap and effective for the quality control of a wide range of 
pharmaceutical preparations. Guidelines for quality must be taken into account during the production of 
such test kits to enable a pharmacist-analyst to fully perform his tasks using these analytical tools. 
The aim of the work is to analyze the risks that may occur during the lifecycle of test systems; to establish 
the risks that have the biggest impact on quality control of compounded preparations with these analytical 
tools and to determine the major ways to minimize the impact of risks at all stages of work with test systems.
MATERIALS AND METHODS: Ishikawa diagrams and Failure Mode, Effects and Criticality Analysis 
(FMECA) were used to analyze the risks during the lifecycle of test systems. Data were received through 
“brainstorming session” and questioning respondents that were related to the development and practical 
use of these analytical tools.
RESULTS: According to the results Risk Priority Number (RPN) for each of the stages of the lifecycle of 
the test systems has been calculated. The highest values of RPN are observed at the stages of manufacturing 
of the test systems (54.95%), the quality control (21.93%) and the use of the test systems (18.66 %). Each of 
the stages of the lifecycle of the test system consists of a number of phases; the most important among them 
are: preparation of the reagent solution – 20.24%; chemical analysis – 17.93%; visual fixation of results 
– 9.21% and training of the personnel – 8.89%.
CONCLUSIONS: The recommendations concerning minimization of risk throughout the lifecycle of test 
kits were developed relying on the results. Optimization in accordance with these guideline procedures of 
manufacturing, quality control, storage and using these test systems allows to ultimately get high-quality 
analytical tools for the quality control of compounded preparations.
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INTRODUCTION
Quality control of the compounded prepara-
tions is not the only uncontested mechanism of en-
suring the quality of medicines. Methods of risk 
analysis and management in the pharmaceutical in-
dustry are implemented in many countries (1, 2), in-
cluding Ukraine, in accordance with the guideline 
ICH-Q9 «Quality Risk Management”. The recom-
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storming”, the main stages of the life cycle of test sys-
tems have been allocated with further distribution of 
these risks. The Ishikawà s diagrams were construct-
ed with attraction of specialists who participated in 
the designing, manufacturing and use of these ana-
lytical tools.
Failure Mode, Effects and Criticality Analy-
sis (FMECA) has found application in pharmacies 
in Europe (9). This method of analysis was impor-
tant for us because of the possibility of digital expres-
sion of risks - determining Risk Priority Number 
– (RPN). RPN is the product probability of occur-
rence of risk (O), severity of risk (S) and probability 
of detection of risk (D), calculated for each individu-
al risk. To assess each factor a 10-point scale provid-
ed in (8) has been used. The priority number of risk 
was calculated using the following formula based on 
the data (7,10):
RPN = S*O*D
The data were obtained by questioning respon-
dents – pharmacists and laboratory technician assis-
tants who participated in the development, manu-
facturing, quality control and use of test-systems de-
scribed in (4-6). 30 specialists were interviewed.
RESULTS AND DISCUSSION
Ishikawà s diagrams or Fishbone diagrams
The factors that have a negative impact on the 
quality control of compounded preparations by us-
ing the test kits reflect in the Ishikawa diagram on 
Figure 1. The risks are distributed in 4 stages: the 
risks of manufacturing, quality control, use and stor-
age of the test kits; the impact of personnel training 
is presented separately, as it has influence on all stag-
es of the lifecycle of test kits.
The largest group of risks is the risks that 
impact the process of manufacturing of the test kits. 
We have represented it separately in the Figure 2.
Figure 1 and Figure 2 show the stage of the 
manufacturing of test systems has the largest num-
ber of risks of the first and second order. This situa-
tion is associated with a large number of operations 
at this stage (Table 1).
mendations of this guideline can be applied not only 
to the pharmaceutical companies, but also in the 
pharmacies, which are engaged in compounding and 
dispensing preparations (3). 
With the purpose of express analysis of com-
pounded preparations test systems containing heavy 
metals were developed. In previous publications the 
use of test kits based on filter paper and modified 
with reagents has been discussed (4-6). Using such 
test systems and physical immobilization of reagents 
makes the preparation of test kits easily available in 
pharmacies. Creation of simple, cheap and standard-
ized test systems, with reagents that worked well dur-
ing the macroanalysis is important and can greatly 
simplify the process of in-pharmacy quality control. 
Implementation of new processes – preparation of 
test systems in compounding pharmacies, making 
mistakes can lead to the incorrect evaluation of the 
quality of compounded preparations. Test systems 
are the tools used for quality control of medicines so 
the requirements for analysis and risk management 
can be extended to all stages of the lifecycle of these 
analytical tools.
The aim of the work is to analyze the risks that 
may occur during the lifecycle of test systems; to es-
tablish the risks that have the biggest impact on qual-
ity control of compounded preparations with these 
analytical tools and to determine the major ways to 
minimize the impact of risks at all stages of working 
with test systems.
MATERIALS AND METHODS
Potential risks and ways to avoid them dur-
ing the lifecycle of test system based on filter paper 
impregnated with the salts of heavy metals FeCl3, 
CuSO4, CoCl2 are discussed in the article. Methods 
concerning manufacturing, storage and using these 
test systems were described in previous publications 
(4-6).
The following tools were used to analyze the 
risks during the lifecycle of test systems: Ishikawa di-
agrams or Fishbone diagrams and Failure Mode, Ef-
fects and Criticality Analysis (FMECA).
Ishikawà s diagrams have wide application in 
various fields of human activity; they can also be ef-
fectively used in pharmacy, including in the work 
of a pharmacy shop (7, 8). The analysis of potential 
risks was conducted using the method of “brain-
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Failure Mode, Effects and Criticality Analysis
The risks and their possible effects were an-
alyzed in more details by questioning the special-
ists, followed by the processing of data using FME-
CA. The results of the questioning about the risks 
and their consequences that may occur at each phase 
of all 4 stages of the lifecycle of test systems are pre-
sented in Table. 1. The 35 risks were selected, some 
of which are repeated, as they are typical for differ-
ent phases and have different effects on each of them. 
In particular, this applies to training of the person-
nel that, unlike Ishikawa diagrams, is not submitted 
in a separate group. The absolute and relative values 
of RPN for each risk at all stages of the lifecycle of the 
test system are presented in Table 1.
The percentage of impact of each stage and 
phase on the overall value of RPN was calculated af-
ter statistical processing of the questionnaires. The 
results are presented in Table 2.
Table 1 shows: the manufacturing of the test sys-
tems has the highest rate of RPN – 54.95%, due to the 
large number of phases and the risks at each phase; 
the quality control and the use of the test systems 
also make a significant contribution in the overall 
value of RPN: RPN (Quality control) – 21.93%, RPN 
(Using) – 18.66%. Selected stages contain different 
number of phases, and as result, different number of 
risks, and so more detailed look should be taken at 
the risks that may occur at each phase of the lifecycle 
of the test systems:
 preparation of the reagent solution – 20.24%; 
this high index is caused by a large number of 
operations, errors of which have a high threat to 
receive a defective test system;
 chemical analysis – 17.93%; the risks that occur 
at this phase include the use of invalidated anal-
ysis methods and reagents that do not comply 
with the requirements of pharmacopoeias, in-
correct concentration of the reagent on the sur-
face of the test system, which can cause narrow-
ing of the range of application of a test system;
 visual fixation of results has RPN of 9.21%. Fail-
ure to comply with the time period of observa-
tion, the absence of blank experiment and the 
problems with fixing results (presence of im-
purities, which can be able to disguise the ana-
lytical effect of the studied component) are the 
main risks at the this phase;
 training of the personnel, this factor has a low 
value of RPN at each of the stages, but the to-
tal value of “human factors” is 8.89  %, which 
indicates the inadmissibility of ignoring the in-
crease of the quality of the personnel training;
 the physical immobilization is an important 
phase (8.54%) – errors, which take place at this 
phase can influence the concentration of re-
agents at the surface of test-system and expira-
tion date;
 the phases of preparation of filter paper (7.94%) 
and analysis (4.73%) have high index of RPN, 
because of the defects of filter papers and the re-
alization of experiments without blank experi-
ment, respectively;
 packaging and labeling of the test systems (5.79%) 
and control of the storage conditions (3.18%) also 
require increased attention, risks at these phas-
Figure 1. The influence of risks of the use of test systems 
on the quality control of compound preparations
Figure 2. The risks that impact the process of manufac-
turing of test systems
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1.1. Preparation of 
the workplace
1. Unsatisfactory sanitary 
treatment of rooms, 
equipment, personnel
Chemical contamination of test 
system. Invalid results of the 
analysis.
5 3 4 60 1.82
2. Wrongly selected 
chemical ware
Inappropriate concentration 
of reagent. Increased time for 
manufacturing of solution of the 
desired concentration (adjusting 
the concentration and repeated 
quantitative determination).
5 3 5 75 2.27
1.2. Preparation of filter paper sheets
1.2.1. Selection of 
paper type 1. Paper defect
Invalid results of the analysis 
(high probability of false positive 
or false negative result). Incorrect 
concentration of the reagent on the 
surface of the test-system. Reduc-
tion of the test system`s expiration 
date. The test system is unusable.
7 4 4 112 3.39
1.2.2. Cutting 
paper into sheets 
of a specified size 
(50*80 mm)
1. Inappropriate number 
of strips from one sheet
Increasing expenses and time for 
production of one test system.
Different concentrations of the 
reagent on different strips from the 
same sheet. Invalid results of the 
analysis.
6 5 5 150 4.54
1.3. Preparation of reagent solution (as required by State Pharmacopoeia of Ukraine)
1.3.1. Sampling
1. Error during reagent 
selection The test system is unusable. 8 4 3 96 2.91
2. Error during sampling
Inappropriate concentration 
of reagent. Increased time for 
manufacturing of solution with the 
desired concentration (adjusting 
the concentration and repeated 
quantitative determination).
6 3 4 72 2.18
3. Using not appropriately 
calibrated equipment 6 3 4 72 2.18
4. Ignoring the moisture 
content, impurities 6 4 4 96 2.91
1.3.2. Dissolution 
and removing 
the solvent to the 
mark
1. Wrongly selected 
chemical ware 5 3 4 60 1.82
2. Errors during removing 
the solvent to the mark 5 3 4 60 1.82
1.3.3. Quality con-
trol of the com-
pound solution 
1. Using a invalidated 
analysis methods and 
reagents that do not 
respond the requirements 
of pharmacopoeias
Decrease of the quality of analy-
sis. Invalid results of the analysis. 
Increasing expenses and time for 
production of test systems
8 4 4 128 3.88
2. Inconsistency in terms 
of sampling, analysis, 
recording results 7 3 4 84 2.54
1.4. Physical immobilization
Table 1. Assessment of occurrence, severity and detection of the risks throughout the lifecycle of test kits
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1.4.1. Control of 
the coverage level 
and area of the 
sheet
1. Partial immersion of a 
sheet in a solution 
Different concentrations of the 
reagent on different strips from the 
same sheet. Invalid results of the 
analysis.
8 4 3 96 2.91
2. The inflection of sheets
Inappropriate number of strips 
from one sheet.
5 3 4 60 1.82
3. The breach of sheet 
parts 5 2 3 30 0.91
1.4.2 Control of 
the time of im-
mobilization
1. Incorrect concentra-
tion of the reagent on the 
surface of the test-system
Invalid results of the analysis. 
Reduction of the test system`s 
expiration date.
6 4 4 96 2.91
1.5. Drying the test system
1.5.1. Control of 
the remainder of 
the moisture 
1. Excess of moisture
Errors of the separation of sheets 
into strips. The break of test-
systems.
4 3 4 48 1.45
1.5.2. Control of 
the drying condi-
tions
1. Failure to comply dry-
ing conditions (time, light, 
temperature)
Reduction of the test system`s 
expiration date. Invalid results of 
the analysis.
6 3 5 90 2.73
1.6. Cutting of 
sheet into the test-
strips
1. Contradiction of size to 
that specified in the docu-
mentation (50*5 mm)
Inappropriate number of strips 
from one sheet. Invalid results 
of the analysis. The test system is 
unusable.
4 2 3 24 0.73
2. The break of sheet 5 2 3 30 0.91
1.7. Packaging and 
labeling of test-
systems
1. Inappropriate storage 
containers
Reduction of the test system`s 
expiration date. Invalid results 
of the analysis. The test system is 
unusable.
8 3 3 72 2.18
2. Bad sealing containers 7 4 2 56 1.70
3. Preparation of labels False labeling. 7 3 3 63 1.91
1.8. Training of 
the personnel
1. Unsatisfactory quality 
of training
Invalid results of the analysis. The 
test system is unusable. Reduction 
of the test system`s expiration date. 
Decrease of the quality of analy-
sis. Invalid results of the analysis. 
Increasing expenses and time for 
production of test-systems.
















m 2.1. Organoleptic 
analysis
1. Defect (size, color 
intensity, damage of a test-
system)
Invalid results of the analysis. The 




1. Using invalidated analy-
sis methods and reagents 
that do not respond the 
requirements of pharma-
copoeias
Decrease of the quality of analy-
sis. Invalid results of the analysis. 
Increasing expenses and time for 
production of test-systems.
The test system is unusable.
7 4 4 112 3.39
2. Inconsistency in terms 
of sampling, analysis, fix-
ing results
7 4 4 112 3.39
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2.2.2. Quantitative 
analysis
1. Using invalidated analy-
sis methods and reagents 
that do not reply the 
requirements of pharma-
copoeias
Decrease of the quality of analy-
sis. Invalid results of the analysis. 
Increasing expenses and time for 
production of test systems. Invalid 
results of the analysis.
The test system is unusable.
7 4 4 112 3.39
2. Inconsistency in terms 
of sampling, analysis, fix-
ing results
7 4 4 112 3.39
3. Incorrect concentration 
of the reagent on the sur-
face of the test system.
6 4 6 144 4.36
2.3 Training of the 
personnel
1. Unsatisfactory quality 
of training
Invalid results of the analysis. The 
test system is unusable. Reduction 
of the test system`s expiration date. 
Decrease of the quality of analy-
sis. Invalid results of the analysis. 
Increasing expenses and time for 
production of test-systems.





ge 3.1. Control of the storage conditions
1. Violation of the expira-
tion date 
Invalid results of the analysis. The 
test system is unusable. 7 3 2 42 1.27
2. Violation of the storage 
conditions (temperature, 
lighting, packaging, air 
access)
Reduction of the test system`s 
expiration date. Invalid results 
of the analysis. The test system is 
unusable.
7 3 3 63 1.91
3.2. Training of 
the personnel
1. Unsatisfactory quality 












4.1. Sampling of 
substances
1. Error during sampling 
of substances
Invalid results of the analysis. 
Damage of a test-system. Leaking 
of substances being analyzed on 
skin, clothing, work surface.
6 4 3 72 2.18
4.2 Analysis
1. Invalid test result (false 
positive or false negative 
result) Invalid results of the analysis.
9 4 2 72 2.18
2. Analysis without blank 
experiment 7 4 3 84 2.54
4.3. Visual fixation 
of results
1. Failure to comply with 
the time period of obser-
vation
Invalid results of the analysis (high 
probability of false positive or false 
negative result).
7 4 4 112 3.39
2. The absence of the 
blank experiment 8 4 3 96 2.91
3. Problems with fixing 
results (presence of impu-
rities)
8 3 4 96 2.91
4.4. Training of 
the personnel
1. Unsatisfactory quality 
of training Invalid results of the analysis. 7 3 4 84 2.54
RPN (ov.) = 3301
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Manufacturing of the test 
system
1.1. Preparation of the workplace
1814 54.95
135 4.09
1.2. Preparation of sheets of the filter paper 262 7.94
1.3. Preparation of the reagent solution 668 20.24
1.4. Physical immobilization 282 8.54
1.5. Drying the test system 138 4.18
1.6. Cutting of sheet into the test strips 54 1.64
1.7. Packaging and labeling of the test systems 191 5.79
1.8. Training of the personnel 84 2.54





2.2. Chemical analysis 592 17.93
2.3. Training of the personnel 84 2.54
Storage
3.1. Control of the storage conditions
147 4.45
105 3.18
3.2. Training of the personnel 42 1.27
Using the test system
4.1. Sampling of substances
616 18.66
72 2.18
4.2. Analysis 156 4.73
4.3. Visual fixation of the results 304 9.21
4.4. Training of the personnel 84 2.54
es can influence the expiration date of the test 
system;
 cutting of sheets into test strips (1.64%) and or-
ganoleptic analysis (1.45%) have low index-
es RPN, due to the high probability of the de-
tection of risks at this phase, and low impact of 
the above risks on quality control of compound 
preparations with the help of test system.
The Ways to Eliminate Possible Risks and 
Their Consequences
There are a number of different risks that affect 
the quality of the analysis using test systems. The fol-
lowing recommendations can be used to minimize 
these risks:
1. Development and validation of new methods 
of the quality control, using calibrated ana-
lytical equipment and reagents that comply 
with the requirements of the State Pharma-
copoeia of Ukraine can minimize the risks at 
the phases of quality control of reagent solu-
tions and test systems.
2. Introduction of the changes in the manufac-
turing process: simultaneous immobilization 
and drying of the series of test systems, can 
decrease risks associated with immobiliza-
tion and drying time and also make it impos-
sible to break and damage the sheets during 
their extraction from the reagent solution.
3. The proper control of packaging and storage 
conditions of test systems;
4. Improving the quality of training for work 
with test systems, development of standard 
operating procedures (SOPs) for work with 
these analytical tools.
CONCLUSIONS
Manufacturing, quality control, storage and use 
of test system based on filter paper impregnated with 
the salts of heavy metals are characterized by a large 
number of different risks that are able to have a nega-
tive impact on the results of chemical analysis of the 
compound preparations using test-systems. The data 
presented in the article allow systematizing and ap-
Table 2. The priority number of risks at all the stages and phases of the lifecycle of test systems
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portioning risks and their consequences of the pri-
ority and developing recommendations to minimize 
the negative effects of these threats.
The quality control of the compounded prepa-
rations using test systems can significantly increase 
the following of the recommendations which are giv-
en in the article.
The list of recommendations is not final; the 
work on improving existing and developing new test 
systems is continued.
Improvement of the quality of these test kits al-
lows incorporating these analytical tools into the list 
of the reagents (National part) that are recommend-
ed by the State Pharmacopoeia of Ukraine.
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